Top Page
Cochlear
(OTC:COH)
Cochlear (COH) vs. iShares MSCI Australia ETF (EWA)
Cochlear Business Overview & Revenue Model
Cochlear Earnings Call Summary
Cochlear Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.24B | 1.94B | 1.64B | 1.49B | 1.35B |
| Gross Profit | 1.67B | 1.47B | 1.23B | 1.08B | 1.01B |
| EBITDA | 579.50M | 487.10M | 475.40M | 451.90M | -181.90M |
| Net Income | 356.80M | 300.60M | 289.10M | 326.50M | -238.30M |
Balance Sheet | |||||
| Total Assets | 2.75B | 2.57B | 2.47B | 2.43B | 2.58B |
| Cash, Cash Equivalents and Short-Term Investments | 513.60M | 555.50M | 629.30M | 609.60M | 930.00M |
| Total Debt | 243.70M | 201.80M | 253.90M | 264.30M | 704.50M |
| Total Liabilities | 904.60M | 819.90M | 779.40M | 736.50M | 1.18B |
| Stockholders Equity | 1.84B | 1.75B | 1.69B | 1.69B | 1.40B |
Cash Flow | |||||
| Free Cash Flow | 299.00M | 266.50M | 299.30M | 198.70M | -288.30M |
| Operating Cash Flow | 388.80M | 362.40M | 376.50M | 265.40M | -157.80M |
| Investing Cash Flow | -105.70M | -125.70M | -138.90M | 279.90M | -509.70M |
| Financing Cash Flow | -323.80M | -310.40M | -220.70M | -495.10M | 1.15B |
Cochlear Technical Analysis
Cochlear Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | AU$20.40B | 55.13 | 20.61% | 1.73% | 6.35% | 5.97% | |
63 Neutral | AU$215.65M | ― | -4.06% | ― | 20.36% | 64.81% | |
59 Neutral | AU$801.38M | 134.88 | 8.30% | ― | 39.19% | 273.91% | |
52 Neutral | AU$209.49M | ― | -52.37% | ― | 471.29% | -4.58% | |
51 Neutral | $7.43B | -0.36 | -45.45% | 2.27% | 22.98% | -2.34% | |
46 Neutral | AU$149.65M | ― | -58.61% | ― | ― | -74.88% | |
41 Neutral | AU$106.69M | ― | -35.20% | ― | 4.68% | -155.42% |
Cochlear Corporate Events
Cochlear Limited has announced the issuance of new ordinary fully paid securities to be quoted on the Australian Securities Exchange (ASX). This issuance is part of an employee incentive scheme, reflecting the company’s ongoing commitment to employee engagement and retention. The move is expected to enhance the company’s operational capabilities and strengthen its market position by aligning employee interests with corporate growth objectives.
The most recent analyst rating on (AU:COH) stock is a Sell with a A$272.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited has announced that it will release its financial results for the fiscal year 2025 on August 15, 2025. The company will host a presentation accessible to analysts and media via webcast or conference call. This announcement is significant as it provides stakeholders with insights into the company’s financial performance and strategic direction, potentially impacting its market position and investor relations.
The most recent analyst rating on (AU:COH) stock is a Sell with a A$272.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited announced the cessation of certain securities, specifically 264 deferred performance rights and 513 service rights, due to unmet conditions as of June 30, 2025. This cessation reflects a lapse in conditional rights, which may impact the company’s capital structure and could have implications for stakeholders regarding the company’s performance metrics and strategic goals.
The most recent analyst rating on (AU:COH) stock is a Sell with a A$272.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited has received FDA approval for its Cochlear™ Nucleus® Nexa™ System and Nucleus Kanso® 3 and Kanso® 3 Nexa Sound Processors, with plans to launch these products in the US by the end of the first quarter of FY26. This approval marks a significant milestone for Cochlear, potentially enhancing its market position in the US and offering advanced hearing solutions to its stakeholders.
The most recent analyst rating on (AU:COH) stock is a Sell with a A$272.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited has launched the Nucleus Nexa System, the world’s first smart cochlear implant system with upgradeable firmware. This system allows users to access future innovations and features through both the implant and sound processor, enhancing the hearing experience. The Nucleus 8 Nexa Sound Processor, part of this system, is the smallest and lightest on the market, offering all-day battery life and advanced power management. The launch marks a significant advancement in cochlear implant technology, potentially improving patient outcomes and reducing clinic visits.
The most recent analyst rating on (AU:COH) stock is a Buy with a A$311.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited has updated its FY25 earnings guidance due to slower-than-expected sales growth, projecting an underlying net profit of $390-400 million. The company anticipates a decline in Services revenue by low double-digits, despite efforts to boost sales with new products like the Nucleus® Kanso® 3 Sound Processor. While cochlear implant units are expected to grow by 10%, growth in developed markets has been hindered by slower market expansion and minor market share losses. The launch of a new cochlear implant system in Europe and Asia Pacific is set for mid-June 2025, with further expansion pending regulatory approvals.
The most recent analyst rating on (AU:COH) stock is a Buy with a A$311.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Cochlear Limited announced a change in the address of its share registry provider, Computershare Investor Services Pty Limited, effective from June 10, 2025. The new location is at Level 4, 44 Martin Place, Sydney, NSW 2000. This change requires all documentation lodgements by member organizations, securityholders, and other parties to be made at the new address. The announcement reflects an operational update that stakeholders need to be aware of to ensure proper correspondence and documentation handling.
The most recent analyst rating on (AU:COH) stock is a Buy with a A$311.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
Pinnacle Investment Management Group Limited has increased its voting power in Cochlear Ltd from 5.01% to 6.09% as of May 14, 2025. This change in substantial holding reflects Pinnacle’s growing influence within the company, potentially impacting Cochlear’s strategic decisions and shareholder dynamics.
The most recent analyst rating on (AU:COH) stock is a Buy with a A$311.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.